康复新液联合美沙拉秦对溃疡性结肠炎的IL-1、IL-8、TNF-α、T细胞亚群水平的影响

摘要/Abstract

摘要： 目的分析在溃疡性结肠炎治疗中应用美沙拉秦结合康复新液对白细胞介素1（IL-1）、白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）、T细胞亚群水平的影响。方法选取2019年1月—2021年5月滨州市中心医院收治的41例溃疡性结肠炎患者作为研究对象,按照随机数表法分为观察组（美沙拉秦联合康复新液,21例）和对照组（美沙拉秦,20例）,比较分析两组治疗后临床疗效、不良反应（恶心、便秘、头晕）发生情况、炎症因子（IL-1、IL-8、TNF-α）水平、T细胞亚群[白细胞分化抗原（CD8⁺）、自然杀伤细胞（NK）、T辅助细胞/T杀伤细胞（CD4⁺/CD8⁺）]水平。结果治疗后,观察组IL-1、IL-8、TNF-α、CD8⁺、NK、CD4⁺/CD8⁺水平与不良反应发生率明显低于对照组,临床疗效高于对照组,差异有统计学意义（P<0.05）。结论在溃疡性结肠炎患者治疗中应用美沙拉秦联合康复新液可显著提高疗效,减少疾病治疗后不良反应发生,较单独应用美沙拉秦治疗更能提高免疫功能,减轻炎症症状。

关键词: 美沙拉秦, 康复新液, 溃疡性, 结肠炎

Abstract: Objective The effects of mesalazine combined with a new rehabilitation solution on the levels of interleukin 1 (IL-1), interleukin-8 (IL-8), tumour necrosis factor- α (TNF-α), and T cell subsets in the treatment of ulcerative colitis disease was analyzed. Methods 41 patients with ulcerative colitis admitted to Binzhou Central Hospital in recent years (2019.1-2021.5) were taken as the observation objects, divided into the observation group according to the random number table method (mesalazine combined with new rehabilitation solution, 21 patients) and controls (mesalazine, In 20 cases), The clinical efficacy, adverse effects (nausea, constipation, dizziness), inflammatory factor levels of IL (IL-1, IL-8, TNF-α), T cell subsets [leukocyte differentiation antigen (CD8⁺), natural killer cells (NK), T helper cells / T killer cells (CD4⁺/CD8⁺)] were compared between the two groups. Results After treatment, the incidence of IL-1, IL-8, TNF-α, CD8⁺, NK, CD4⁺/CD8⁺ and that of adverse reactions in the observation group was significantly lower than that in the control group, the clinical efficacy was higher, and the comparison was statistically significant different (P<0.05). Conclusion In the treatment of ulcerative colitis patients, treatment with mesalazine combined with rehabilitation new solution can significantly improve the efficacy and reduce the incidence of adverse reactions after disease treatment. Compared with mesalazine alone, it can improve the immune function and reduce inflammatory symptoms.

Key words: mesalazine, rehabilitation new fluid, ulcerative, colitis

中图分类号:

R574.62

张秋芹. 康复新液联合美沙拉秦对溃疡性结肠炎的IL-1、IL-8、TNF-α、T细胞亚群水平的影响[J]. 中华养生保健, 2023, 41(22): 12-15.

ZHANG Qiu-qin. Effect of Rehabilitation New Fluid Combined with Mesalazine on the Levels of IL-1, IL-8, TNF-α, and T Cell Subsets in Ulcerative Colitis[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(22): 12-15.

参考文献

[1] 李雪可,康欣,赵源,等.自拟泄浊解毒方联合美沙拉嗪治疗溃疡性结肠炎患者临床疗效观察[J].疑难病杂志,2022,21(10):1040-1046.
[2] KOCH T R.结肠疾病(精)[M].北京:人民卫生出版社,2006:23-26.
[3] 陈曦,欧阳钦,胡仁伟,等.我国溃疡性结肠炎治疗性研究文献分析[J].四川医学,2005,26(4):376-378.
[4] 陈文旭,张建惠.美沙拉嗪+双歧杆菌三联活菌治疗溃疡性结肠炎的临床效果及对炎性因子水平的影响[J].中国现代医药杂志,2022,24(9):67-70.
[5] 许若思,陈露,黎慧娟.美沙拉秦栓联合康复新液保留灌肠治疗活动期溃疡性结肠炎的临床效果[J].临床合理用药杂志,2022,15(26):26-29.
[6] 姚志刚,杨维维.锡类散灌肠联合美沙拉嗪治疗湿热型溃疡性结肠炎的临床疗效及对疾病活动指数的影响[J].中国处方药,2022,20(9):138-140.
[7] 侯朝军. 柳氮磺胺吡啶联合康复新液对溃疡性结肠炎患者肠道黏膜NF-κB、TLR-4表达及免疫功能的影响[J].反射疗法与康复医学,2022,3(10):119-121.
[8] 张文君,刘谦,夏兴洲.培菲康联合美沙拉嗪及康复新液治疗溃疡性结肠炎的效果[J].精准医学杂志,2022,37(2):147-150,156.
[9] 韩秀芳,余艳兰,曾婷婷,等.水罐疗法联合康复新液保留灌肠对溃疡性结肠炎患者血清神经内分泌因子的影响[J].中医外治杂志,2022,31(2):4-6.
[10] 郝永彪. 青黛灌肠液灌肠联合美沙拉嗪治疗溃疡性结肠炎对患者症状改善和黏膜愈合的疗效观察[J].辽宁中医杂志,2021,48(8):137-140.
[11] 刘暘. 美沙拉嗪联合康复新液治疗溃疡性结肠炎的临床效果观察[J].基层医学论坛,2022,26(2):124-126.
[12] 罗华. 康复新液联合美沙拉嗪治疗溃疡性结肠炎患者的效果[J].医疗装备,2021,34(10):114-115.
[13] 李红. 康复新液口服加灌肠联合美沙拉嗪治疗溃疡性结肠炎的疗效分析[J].中国医药指南,2018,16(35):182.
[14] 张艳凯,高翔,王金玉,等.康复新液联合美沙拉嗪对老年溃疡性结肠炎患者疗效分析[J].实用临床医药杂志,2020,24(21):25-28.
[15] 李兆雷. 康复新液结合美沙拉嗪对溃疡性结肠炎患者免疫指标的影响[J].中国医学创新,2020,17(20):143-146.
[16] 丛龙玲,姚嘉茵,吴宇金,等.肠炎清合剂联合美沙拉嗪肠溶片维持治疗缓解期溃疡性结肠炎的临床疗效[J].中国实验方剂学杂志,2021,27(3):99-104.
[17] 陈立冬,刘智慧,于蕊.康复新液灌肠联合美沙拉嗪治疗溃疡性结肠炎疗效研究[J].陕西中医,2019,40(9):1187-1189.